Followers
0
Following
1
Blog Posts
0
Threads
52
Blogs
Threads
Portfolio
Follower
Following
2023-12-22 10:53 | Report Abuse
SEE you at RM2.5
2021-11-18 19:35 | Report Abuse
FPI zero debt and net cash RM215m or RM0.85/share, pay 20 cents per year also can sustain dividend for 4 years if close shop today :)
2021-11-18 18:47 | Report Abuse
no dividend policy but the payout keep increasing. maybe coming one is 20c??
2021-11-18 18:46 | Report Abuse
buy now or forever hold your peace! at least not making losses like ATA..
2021-10-20 09:26 | Report Abuse
CFTC is a venture capital firm incorporated by China’s largest pure play semiconductor foundry, Semiconductor Manufacturing International Corporation (SMIC)
2021-08-26 18:39 | Report Abuse
good results but auditor Deloitte resigned!!!
2021-02-01 23:19 | Report Abuse
retailers were the biggest net seller of TG last friday! waliauuu
2020-08-26 09:02 | Report Abuse
Supermax june quarter RM400m
Harta june quarter RM220m
Kossan june quarter RM131m
Supermax > Harta + Kossan in profits
Supermax market cap RM26b
Harta market cap RM57b
Kossan market cap RM19b
Supermax is 1/3 of Harta + Kossan in market cap
2020-08-11 16:31 | Report Abuse
buy all the way down!!!!!
2020-08-10 22:53 | Report Abuse
looks like everyone is ready to sell tomorrow!! because it will be too late to sell after the next results...;)
2020-06-18 12:21 | Report Abuse
possible if gov needs more $$$, shareholders zzzzz
2020-06-18 12:20 | Report Abuse
maybe windfall tax is coming?! similar to CPO
2020-06-18 12:19 | Report Abuse
windfall tax coming?! same like when cpo price shot up
2020-06-14 20:15 | Report Abuse
https://www.bloomberg.com/news/articles/2020-06-14/sinovac-s-vaccine-t...
Sinovac Biotech Ltd. said its coronavirus shot is safe and capable of eliciting an immune response from human trials, suggesting the shot’s potential in defending against infection of the novel coronavirus.
The Beijing-based company’s vaccine, called CoronaVac, hasn’t caused severe side effects and more than 90% of people administered with the shot on a 14-day interval have induced neutralizing antibodies two weeks after inoculation, Sinovac said in a press release on Sunday.
The preliminary findings come from phase I and II trials in China. A total of 743 healthy people ages 18 to 59 either received shots on two schedules or a placebo. More data will be uncovered from another group in the trial that received shots on a 28-day interval. Sinovac plans to publish its results in academic journals, according to a company spokesman.
Using a killed version of the coronavirus, Sinovac’s vaccine is among five Chinese experimental shots that have reached the crucial final stage of human testing before they can be approved for public use. The company announced a partnership this month with Instituto Butantan to conduct its phase III trial in Brazil, where the novel pathogen has caused the second-largest outbreak in a global pandemic that so far infected more than 7.7 million people and killed over 428,000.
Since lockdowns and social-distancing measures have helped to keep infection rates low in many countries, some of the world’s leading vaccine efforts are seeking to conduct phase III trial in active outbreaks to evaluate the effectiveness of their shots.
Authorities in Brazil have approved the vaccine co-developed by the University of Oxford and AstraZeneca Plc to carry out late stage trials there, while Cambridge, Massachusetts-based Moderna Inc. is set to go into phase III trials in the U.S.
2020-06-14 20:13 | Report Abuse
https://www.bloomberg.com/news/articles/2020-06-14/sinovac-s-vaccine-trial-data-suggest-potential-in-virus-defense
Sinovac Biotech Ltd. said its coronavirus shot is safe and capable of eliciting an immune response from human trials, suggesting the shot’s potential in defending against infection of the novel coronavirus.
The Beijing-based company’s vaccine, called CoronaVac, hasn’t caused severe side effects and more than 90% of people administered with the shot on a 14-day interval have induced neutralizing antibodies two weeks after inoculation, Sinovac said in a press release on Sunday.
The preliminary findings come from phase I and II trials in China. A total of 743 healthy people ages 18 to 59 either received shots on two schedules or a placebo. More data will be uncovered from another group in the trial that received shots on a 28-day interval. Sinovac plans to publish its results in academic journals, according to a company spokesman.
Using a killed version of the coronavirus, Sinovac’s vaccine is among five Chinese experimental shots that have reached the crucial final stage of human testing before they can be approved for public use. The company announced a partnership this month with Instituto Butantan to conduct its phase III trial in Brazil, where the novel pathogen has caused the second-largest outbreak in a global pandemic that so far infected more than 7.7 million people and killed over 428,000.
Since lockdowns and social-distancing measures have helped to keep infection rates low in many countries, some of the world’s leading vaccine efforts are seeking to conduct phase III trial in active outbreaks to evaluate the effectiveness of their shots.
Authorities in Brazil have approved the vaccine co-developed by the University of Oxford and AstraZeneca Plc to carry out late stage trials there, while Cambridge, Massachusetts-based Moderna Inc. is set to go into phase III trials in the U.S.
2020-06-08 22:31 | Report Abuse
please be careful, otb and kyy are switching to supermax. maybe they know comfort profit potong stim like careplus
2020-06-07 22:41 | Report Abuse
once topglove plus harta cross 10% of KLCI, $$$ will pour into this sector. supermax will enter klci too and fly like a superman
2020-06-07 21:49 | Report Abuse
UG is obm just like supermax, benefit the most during this pandemic
2020-06-01 23:12 | Report Abuse
https://ec.ltn.com.tw/article/breakingnews/3183126
price fell so much
2020-05-27 17:34 | Report Abuse
yea Topglove was way back in 2013, old history and they will surely be aware and have learnt their lesson
2020-05-27 17:08 | Report Abuse
https://www.accessdata.fda.gov/cms_ia/importalert_229.html
is this fake news?
2017-03-09 23:36 | Report Abuse
regardless, theres also only one broker started to cover ekovest quite late, but look at the return
2016-03-22 21:37 | Report Abuse
yes i also agree with the point that Airasia will benefit very much from weak Dollar
2016-03-22 21:35 | Report Abuse
sell and wait for the next entry...
2016-03-22 21:32 | Report Abuse
Brussels attack happened mid of today, not after market closed
2016-03-21 15:53 | Report Abuse
the closest human race ever get to curing Alzheimer
2016-02-28 22:40 | Report Abuse
Monday sure fly! there was a huge one-off gain last year stated in the QR while this year those are real earnings
2016-02-22 23:48 | Report Abuse
why for this company the borrowings are so high? for property development? is the earnings from property development sustainable?
2016-02-18 22:06 | Report Abuse
thanks jay_j i am newbie. but looks like crude oil price no longer drag MYR in recent months
2016-01-24 17:38 | Report Abuse
is the contact lens business a long shot?
Blog: KELINGTON GROUP (0151) SOME RED FLAGS IN THIS STOCK YOU NEED TO KNOW, Calvin Tan
2023-12-22 11:01 | Report Abuse
bla bla bla